As emavusertib mainly targets TLR signaling, it would be merited to evaluate the combination of an anti-CD20 monoclonal antibody with emavusertib in B-cell NHL to see if there is synergism between the two therapies and also the combination of emavusertib with anti-CD19 monoclonal antibodies which have shown single agent efficacy in B-cell NHL (88). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.